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Objectives: Robust scientific evidence exists about the role of non-conventional
risk factors in type 2 diabetes worldwide. The current epidemiological pattern of
the disease in Iran suggests a precipitating role for these non-conventional risk
factors. This review was performed to examine the research evidence suggesting
a higher prevalence of non-conventional type 2 diabetes risk factors in Iran.
Methods: MeSH keywords were applied to search several databases, including
PUBMED, MEDLINE, AMED, EMBASE, Iran DOC, and the Scientific Information Data-
base without a time limit from inception to September 2011. The quality of the non-
interventional and population-based studies on Iranians included in these databases
was assessed by the authors and any disagreement was resolved with consensus.
Results: The literature search yielded 1847 publications, of which 62 were
included in this study after eliminating non-relevant and overlapping papers. No
study was found that verified a higher prevalence of the non-conventional type 2
diabetes risk factors in the Iranian population.
Conclusion: The identified evidence gap about the role of prominent non-
conventional risk factors of type 2 diabetes in the Iranian population could be a
major caveat in the application of an evidence-based approach to endorse or
reject existing hypothesis about these risk factors. Studies on the prevalence of
non-conventional biomarkers of type 2 diabetes among Iranians could be a
promising area of research.1. Introduction
Type 2 diabetes is a highly prevalent metabolic dis-
order and accounts for about 90% of all cases of diabetes& Promotion Department,
iz, Iran.
ghaghi@gmail.com (A. Sha
ted under the terms of the
) which permits unrestrict
operly cited.
ase Control and Preventionin the world [1]. The global prevalence of type 2 diabetes
has reached 6.4%, which could be an overwhelming
burden on the health and economies of countries [2].
Although there is robust scientific evidence about the roleFaculty of Health, Attar Neishabouri Ave., Tabriz University of
ghaghi).
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Risk factors for type 2 diabetes in Iran 293of conventional risk factors and, consequently, about
effective preventive strategies to halt the progress of the
disease worldwide, the marked increase in type 2 diabetes
in recent decades represents a failure in putting the
established science into practice [3].
The prevalence of type 2 diabetes among adult Ira-
nians aged 25e64 years is estimated to be 7.7%,
excluding undiagnosed patients [4]. Lifestyle changes,
especially in urban areas, low rates of physical activity,
and obesity are the main recognized conventional trig-
gers in the occurrence of type 2 diabetes across the
country [5]. The onset of the disease in Iran is currently
mostly observable in the 45e55 year age group, whereas
in the developed world it is mainly a disease of old age,Figure 1. Flow diagram of the method of selecting publications
databases.i.e., over the age of 65 years [6]. Such a difference may
be due to a higher prevalence of conventional and non-
conventional type 2 diabetes risk factors in Iran.
Lower plasma creatinine [7], a high intake of total
and animal protein [8], plasma apelin and visfatin levels
[9,10], lower b-cell function [11], plasma preptin levels
(a hormone that is co-secreted with insulin and amylin
from the pancreatic b cells) [12], serum 25-
hydroxyvitamin D (25OHD), and dietary calcium
[13e16] are a group of non-conventional risk factors
that may explain the higher incidence and prevalence of
type 2 diabetes in some ethnic groups.
This study was performed to look at the empirical
research evidence about the studied risk factors for type 2on the risk factors of type 2 diabetes in Iran retrieved from
294 A. Shaghaghi, A. Ahmadidiabetes in the Iranian population and to check whether
therewas any hypothesis to suggest a higher prevalence of
non-conventional type 2 diabetes risk factors in Iran.2. Materials and methods
In this systematic review, various keywords
(including “type 2 diabetes”, “diabetes mellitus”,
“maturity onset diabetes” or “noninsulin-dependent
diabetes”, and “Iran” and “risk factor” with their Persian
equivalents) were applied to search the PUBMED,
MEDLINE, AMED, CINAHL, EMBASE, SCOPUS,
and MEDLIB databases, and also the Scientific Infor-
mation Database (SID; a national database of published
articles in Iranian journals) and IRAN DOC (a database
of published papers and thesis in Iran) without a time
limit from inception to September 2011. The Super
Searcher of Google Scholar was also checked for un-
published materials within the same time limit. All non-
interventional population-based studies on Iranians
living in Iran were included, but studies on people living
in institutions, Iranians living abroad, and publications
in non-English or non-Persian languages were excluded.
A customized data extraction sheet was used to extract
and record the study data. The quality of the studies was
determined based on the study design, sample size,
sampling method, sampling frame, study feature, and a
report of the type of conventional and non-conventional
type 2 diabetes risk factors studied. The quality of the
retrieved publications based on these quality criteria were
assessed independently by the authors and any
disagreement was resolved with consensus.Table 1. Studied risk factors of type 2 diabetes in the
Iranian studies retrieved from databases.
Risk factor No. (%) of publications
Obesity and waist size 51 (82.1)
Hypertension 25 (40.3)
Dislipidemia 25 (40.3)
Old age 20 (32.2)
Female sex 14 (22.5)
Family history 14 (22.5)
Lifestyle 13 (20.9)
Smoking 11 (17.7)
Urbanization 6 (9.6)
Waist to hip ratio 6 (9.6)
Educational level 4 (6.4)
Stress and anxiety 4 (6.4)
Frequent pregnancies 3 (4.8)
Waist to height ratio 2 (3.2)
Polycystic ovary syndrome 1 (1.6)
Use of some drugsa 1 (1.6)
aPhenytoin (Dilantin), diuretics (thiazides), corticosteroids, beta
blockers, and steroids (contraceptives).3. Results
We found 1836 publications in the first round of the
search, along with 11 publications found through
serendipitous discovery. The titles and abstracts of these
identified publications were inspected and their rele-
vance to the objective of this study was checked. As a
result of overlaps among the scanned databases or in-
consistencies with the study objectives, 1610 publica-
tions were excluded. Of the remaining publications
(226), 150 papers were also excluded after they had
been scrutinized in detail for inclusion and quality
criteria. The full text of 76 publications were obtained at
this stage and were studied thoroughly. Finally, 14
publications were excluded because they were not
directly relevant to the study objectives. Consequently,
62 publications [17e74] were included in this review
(Figure 1).
The risk factor most often studied in the selected
publications was obesity and waist circumference; the
least studied risk factors were polycystic ovary syndrome
and the use of specific types of drugs, such as phenytoin(Dilantin), diuretics (thiazides), corticosteroids, beta
blockers, and steroids (contraceptives; Table 1).The
applied cutoff points to assign abnormality in the
retrieved studies are given in Table 2. Data about the year
of publication of the included publications are given in
Table 3.
We found no study focused on the prevalence of non-
conventional type 2 diabetes risk factors in the Iranian
population, nor any hypothesis explaining a probable
higher prevalence of non-conventional risk factors for
type 2 diabetes.4. Discussion
The findings of this study revealed a major gap in the
study of prominent non-conventional risk factors for
type 2 diabetes in the Iranian population. Obesity and
waist circumference were among the most frequently
studied risk factors that have been screened as predictors
of type 2 diabetes in Iran. Inconsistency in the applied
cutoff points of the studied risk factors compared with
internationally agreed recommendations was noticeable
in these studies [75]. To the best of our knowledge, this
is the first systematic review investigating scientific
evidence about the prevalence of non-conventional risk
factors of type 2 diabetes in Iran. Although there is
empirical research evidence suggesting that identified
non-conventional type 2 diabetes risk factors might play
a part in the incidence of the disease [76e78], no
research evidence was identified to endorse or reject a
higher prevalence of non-conventional type 2 diabetes
risk factors in Iran. This should be considered as a major
caveat in the application of an evidence-based approach
Table 2. Cutoff point applied to indicate a higher risk of
type 2 diabetes in the Iranian studies retrieved
from databases.
Obesity BMI > 25 kg/m2
Waist size > 102 cm in men and
> 88 cm in women
Hypertension Systolic blood pressure
> 140 mmHg and
diastolic blood
pressure
> 90 mmHg
Dislipidemia
Triglycerides > 150 mg/dL
(1.69 mmol/L)
HDL cholesterol < 40 mg/dL
(1.03 mmol/L)
Total cholesterol > 200 mg/dL
(5.17 mmol/L)
Old age > 65 years
Waist to hip ratio > 0.9 in me and > 0.8
in women
Waist to height ratio > 0.5
BMI Z body mass index; HDL Z high-density lipoprotein.
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the burden of the disease.
Selection bias due to limited accessibility to all the
relevant international databases, a lack of access to
published work in Iran due to the absence of an inte-
grated database of scientific publications, and inclusion
criteria of selecting only publications in the English and
Persian languages were major methodological sources
of bias in this review. Therefore the study results must
be considered with caution.
The findings of this study, regardless of the inherent
limitations, highlight a major gap in studying the epide-
miology of type 2 diabetes in Iran and demonstrated the
inadequacy of scientific evidence to precisely explain the
triggering factors for the epidemic in the country. The
paucity of scientific evidence to inform the national type 2
diabetes care protocol may explain and even broaden the
current identified gaps in the Iranian type 2 diabetes care
protocol [79]. As a promising area of study, we invite
researchers to work on the prevalence of the prevailingTable 3. Year of the publication of the Iranian studies on
the risk factors of type 2 diabetes retrieved from
databases.
Year of publication No. (%) of publications
2011e2010 17 (27.4)
2009e2008 25 (40.0)
2007e2005 9 (14.5)
2004e2000 9 (14.5)
1999e1995 2 (3.2)non-conventional type 2 diabetes biomarkers and also on
any hypothetical non-identified biomarker that could
potentially clarify whether any non-conventional type 2
diabetes risk factors may explain the current expanding
pattern of the disease in Iran.Conflicts of interest
The authors declare no competing or conflict of
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